Endocrine Abstracts

JOINT1807

Aims: We decided to study the effectiveness of cinacalcet in dialysis patients in the Uzbek population.

Method: We randomly selected 50 patients (28 men and 22 women) on dialysis in our center. We divided the patients into two groups: group A consisted of 30 patients who were prescribed cinacalcet at a dose of 30 mg/day in addition to the treatment, and group B consisted of 20 patients who served as a control group. The patients were examined for 3 months, the control points were the 30th and 90th days. Both groups were similar in calcium, vitamin D and PTH levels, and ultrasound parameters.

Results: The indices of MBD improved in group A in relation to group B. The calcium level in patients of group A before treatment was 2.48±0.47 mmol/l and significantlydecreased after treatment, amounting to 2.17±0.38 mmol/l (P<0.05). In group B, it was 2.51±0.56 mmol/l and 2.49±0.97 mmol/l (P>0.05), respectively. Blood phosphorus in group A, according to the results of 90 days, decreased from².83±0.86 mmol/l to 1.72±0.76 mmol/l, and in group B from 2.81±0.91 mmol/l to 2.73±0.65 mmol/l. Before the study, the PTH level in group A was 1132.3±182.7 pg/ml, in group B – 1083.9±169.3 pg/ml. After 30 days of the study, in group PTH decreased by 18% and was 928.5±98.7 pg/ml (P<0.05), while in group B it changed insignificantly – 1053.7±158.6 pg/ml (P>0.05). On the 90th day of treatment, the PTH level in group A decreased by another 16%, amounting to 779.9±83.7 pg/ml (P<0.05), thereby decreasing by 31.1% (P<0.05) from the initial level. And in group B it remained at approximately the same level, amounting to 1032.1±143.8 pg/ml. Also, in group A, the symptoms of hyperparathyroidism symptoms such as pain in bones and joints, muscle weakness, fatigue, decreased tone decreased in patientsand the well-being of patients improved, which was not observed in patients in group B. No patient experienced any side effects or intolerance to the drug, and there were no cases of overdose.

Conclusion: A single-center trial of cinacalcet in dialysis patients was found to be quite effective. In patients who received cinacalcet at a dose of 30 mg/day in addition to their current treatment, PTH levels decreased by more than 30% compared to the control group without cinacalcet. Patients taking cinacalcet showed improvement in MBD (calcium, phosphorus) indices. The subjective state of dialysis patients also improved, which confirms the safety of the drug.